Posted by Michael Wonder on 24 Mar 2016
Pfizer announces European Medicines Agency accepted for review its marketing authorisation application for Xeljanz (tofacitinib citrate) for the treatment of moderate to severe rheumatoid arthritis
23 March 2016 - Pfizer announced today that the European Medicines Agency (EMA) has accepted for review the marketing authorisation application (MAA) for Xeljanz (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The EMA will now initiate its review of the XELJANZ MAA.
This application provides additional information to the original MAA submission, including data from the Phase 3 ORAL (Oral Rheumatoid Arthritis Phase 3 TriaLs) global development program in RA. This program consisted of six completed clinical trials, in addition to two open-label long-term extension (LTE) studies, one of which is still ongoing. To date, the ORAL development program has accumulated more than 19,400 patient-years of drug exposure having been studied in more than 6,100 patients including follow-up observations of up to eight years in the LTE study.
